Judy E Garber

List of Publications by Year
in descending order

143 papers	17,257 citations	32410 55 h-index	17373 126 g-index
147 all docs	147 docs citations	147 times ranked	22346 citing authors

#	Article	IF	Citations
1	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. British Journal of Cancer, 2022, 126, 302-309.	2.9	18
2	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	1.1	10
3	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
4	Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition. Cancer Medicine, 2022, 11, 1745-1752.	1.3	6
5	Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer. Cancer Research, 2022, 82, GS4-09-GS4-09.	0.4	3
6	PARP inhibition in breast cancer: progress made and future hopes. Npj Breast Cancer, 2022, 8, 47.	2.3	42
7	Vulvar Melanoma in association with germline MITF p.E318K variant. Cancer Genetics, 2022, 262-263, 102-106.	0.2	2
8	Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clinical Cancer Research, 2022, 28, 2349-2360.	3.2	8
9	Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Research and Treatment, 2022, 193, 417-427.	1.1	11
10	Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics. Cancer, 2022, 128, 1275-1283.	2.0	9
11	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1621-1629.	1.1	2
12	Reply to T. MÃ©nard. JCO Precision Oncology, 2022, , .	1.5	0
13	Histopathologic features of breast cancer in Liâ€“Fraumeni syndrome. Modern Pathology, 2021, 34, 542-548.	2.9	17
14	Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecologic Oncology, 2021, 160, 457-463.	0.6	11
15	A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clinical Cancer Research, 2021, 27, 967-974.	3.2	12
16	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer, 2021, 2, 66-82.	5.7	126
17	Informing models of cancer genetics care in the era of multigene panel testing with patientâ€ed recommendations. Journal of Genetic Counseling, 2021, 30, 268-282.	0.9	5
18	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19

#	Article	IF	Citations
19	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Reports, 2021, 34, 108926.	2.9	16
20	The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. Cancer Prevention Research, 2021, 14, 753-762.	0.7	8
21	Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs). JCO Precision Oncology, 2021, 5, 808-816.	1.5	7
22	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	13.9	764
23	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	1.5	9
24	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
25	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. JCO Precision Oncology, 2021, 5, 307-316.	1.5	18
26	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	0.7	15
27	Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. European Journal of Medical Genetics, 2021, 64, 104359.	0.7	7
28	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55
29	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	1.5	7
30	Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precision Oncology, 2021, 5, 1749-1757.	1.5	10
31	Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data in Brief, 2021, 39, 107653.	0.5	4
32	One step forward, two steps backward. Genetics in Medicine, 2020, 22, 441-442.	1.1	0
33	Patterns of recurrence and metastasis in BRCA1/BRCA2â€associated breast cancers. Cancer, 2020, 126, 271-280.	2.0	74
34	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
35	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genetics in Medicine, 2020, 22, 709-718.	1.1	44
36	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research, 2020, 26, 2704-2710.	3.2	21

#	Article	IF	Citations
37	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
38	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
39	Reply to S. Takamizawa et al. Journal of Clinical Oncology, 2020, 38, 2700-2701.	0.8	2
40	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	2.8	79
41	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	0.8	276
42	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
43	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. JCO Precision Oncology, 2020, 4, 1034-1037.	1.5	6
44	Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562.	1.1	16
45	Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer. Cancer Prevention Research, 2020, 13, 623-634.	0.7	16
46	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	2.3	23
47	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	1.1	7
48	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology, 2020, 4, 585-592.	1.5	41
49	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal of Clinical Oncology, 2020, 38, 1539-1548.	0.8	88
50	Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nature Communications, 2020, 11, 1711.	5.8	134
51	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Caseâ€“Control Analysis Nested within the Nurses' Health Study II. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1264-1270.	1.1	7
52	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
53	â€˜Case of the Monthâ€™ from Brigham and Womenâ€™s Hospital, Boston, MA, USA: a 70â€yearâ€old man with lung cysts and bilateral renal masses. BJU International, 2020, 126, 428-432.	1.3	0
54	Novel Pathogenic Germline Variant of the Adenomatous Polyposis Coli (APC) Gene, p.S2627Gfs*12 Identified in a Mild Phenotype of APC-Associated Polyposis: A Case Report. American Journal of Case Reports, 2020, 21, e927293.	0.3	1

#	Article	IF	Citations
55	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.3	0
56	Novel Pathogenic Germline Variant of the Adenomatous Polyposis Coli (APC) Gene, p.S2627Gfs*12 Identified in a Mild Phenotype of APC-Associated Polyposis: A Case Report. American Journal of Case Reports, 2020, 21, e927293.	0.3	5
57	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.3	3
58	Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties. Breast Cancer Research and Treatment, 2019, 177, 741-748.	1.1	11
59	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast Journal, 2019, 25, 575-577.	0.4	3
60	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 3152-3165.	0.8	117
61	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	2.2	51
62	Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications, 2019, 10, 4182.	5.8	37
63	Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Research and Treatment, 2019, 175, 229-237.	1.1	7
64	Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?. Breast Cancer Research and Treatment, 2019, 175, 1-4.	1.1	8
65	Transâ€counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants. Journal of Genetic Counseling, 2019, 28, 708-716.	0.9	18
66	Genotypeâ€"phenotype associations among panel-based TP53+ subjects. Genetics in Medicine, 2019, 21, 2478-2484.	1.1	17
67	Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11437-11443.	3.3	55
68	Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing. Patient Education and Counseling, 2019, 102, 1558-1564.	1.0	15
69	Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plastic and Reconstructive Surgery, 2019, 144, 12-20.	0.7	1
70	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327.	1.1	31
71	Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. Journal of the National Cancer Institute, 2018, 110, 863-870.	3.0	69
72	Towards Prevention of Breast Cancer: What Are the Clinical Challenges?. Cancer Prevention Research, 2018, 11, 255-264.	0.7	15

#	Article	IF	Citations
73	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prevention Research, 2018, 11, 203-214.	0.7	17
74	Screening with wholeâ€body magnetic resonance imaging in pediatric subjects with Liâ€“Fraumeni syndrome: A single institution pilot study. Pediatric Blood and Cancer, 2018, 65, e26822.	0.8	25
75	A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings. Journal of Community Genetics, 2018, 9, 233-241.	0.5	17
76	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
77	Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers?. Journal of the National Cancer Institute, 2018, 110, 925-926.	3.0	0
78	Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. JAMA Surgery, 2018, 153, 1145.	2.2	12
79	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute, 2018, 110, 855-862.	3.0	225
80	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
81	BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer, 2018, 119, 141-152.	2.9	142
82	Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discovery, 2018, 8, 803-811.	7.7	62
83	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 2017, 19, 787-795.	1.1	46
84	Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecologic Oncology, 2017, 146, 205-214.	0.6	16
85	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
86	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	3.2	358
87	Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Research and Treatment, 2017, 165, 285-291.	1.1	14
88	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
89	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
90	Using machine learning to parse breast pathology reports. Breast Cancer Research and Treatment, 2017, 161, 203-211.	1.1	87

#	Article	IF	Citations
91	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	0.8	15
92	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clinical Cancer Research, 2017, 23, 7351-7359.	3.2	74
93	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
94	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	3.4	148
95	Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discovery, 2017, 7, 1098-1115.	7.7	185
96	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology, 2017, 13, 307-320.	1.1	41
97	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology, 2017, 35, 1179-1188.	0.8	91
98	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
99	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002.	2.3	31
100	The cancer predisposition revolution. Science, 2016, 352, 1052-1053.	6.0	14
101	Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment, 2016, 160, 393-410.	1.1	58
102	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine, 2016, 8, 79.	3.6	151
103	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	0.8	147
104	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
105	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
106	Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 201-206.	1.1	29
107	BRCA1andBRCA2Mutation Testing in Young Women With Breast Cancer. JAMA Oncology, 2016, 2, 730.	3.4	105
108	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	1.1	108

#	Article	IF	Citations
109	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 3764-3773.	3.2	733
110	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1460-1468.	0.8	413
111	Patient Perceptions of Telephone vs. Inâ€Person BRCA1/BRCA2 Genetic Counseling. Journal of Genetic Counseling, 2016, 25, 472-482.	0.9	46
112	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
113	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget, 2016, 7, 13587-13598.	0.8	485
114	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
115	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genetics in Medicine, 2015, 17, 467-475.	1.1	86
116	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	0.8	521
117	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
118	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1902-1909.	0.8	351
119	PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Medicine, 2015, 13, 188.	2.3	221
120	BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nature Communications, 2014, 5, 5496.	5.8	129
121	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	15.2	508
122	GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome. Human Mutation, 2014, 35, 654-662.	1.1	123
123	Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners.. Health Psychology, 2014, 33, 765-773.	1.3	13
124	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
125	Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Research and Treatment, 2013, 139, 193-198.	1.1	38
126	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244

#	Article	IF	Citations
127	Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery, 2012, 2, 366-375.	7.7	464
128	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
129	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	1.1	144
130	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	13.9	847
131	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1145-1153.	0.8	860
132	BRCA1/2-Associated and Sporadic Breast Cancers: Fellow Travelers or Not?. Cancer Prevention Research, 2009, 2, 100-103.	0.7	4
133	Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecologic Oncology, 2009, 115, 108-111.	0.6	24
134	PARP inhibition in breast cancer. Clinical Advances in Hematology and Oncology, 2009, 7, 573-5.	0.3	0
135	Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutations. New England Journal of Medicine, 2002, 346, 1616-1622.	13.9	1,565
136	Commentary on Eccles et al.: familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 73-74.	0.9	0
137	Occult Ovarian Tumors in Women With BRCA1 or BRCA2 Mutations Undergoing Prophylactic Oophorectomy. Journal of Clinical Oncology, 2000, 18, 2728-2732.	0.8	182
138	p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome. Oncogene, 1999, 18, 3970-3978.	2.6	33
139	Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene, 1998, 17, 727-731.	2.6	57
140	Multiple Primary Cancers in Families With Li-Fraumeni Syndrome. Journal of the National Cancer Institute, 1998, 90, 606-611.	3.0	507
141	Acceptance of invitations for p53 and BRCA1 predisposition testing: Factors influencing potential utilization of cancer genetic testing. Psycho-Oncology, 1996, 5, 241-250.	1.0	42
142	Acceptance of invitations for p53 and BRCA1 predisposition testing: Factors influencing potential utilization of cancer genetic testing. , 1996, 5, 241.		1
143	Melanoma and soft tissue sarcoma in seven patients. Cancer, 1990, 66, 2432-2434.	2.0	16